Olga Dontsova is a Full Professor at Moscow State University (MSU) in the Faculty of Chemistry. She serves as Head of the Division of RNA Structure and Function at the Belozersky Institute of Physico-Chemical Biology and Head of the Chair of Chemistry of Natural Compounds. Her research spans molecular biology, bioorganic chemistry, and RNA-based mechanisms. Research Focus: She investigates structure-functional relationships in ribonucleoprotein complexes, with emphasis on translation machinery, transfer-messenger RNA (tmRNA) interactions with ribosomes, RNA methyltransferases, and telomerase's role in cancer. Her team pioneered a chemical-biochemical-genetic approach to map mRNA topography in ribosomes, elucidate trans-translation dynamics, and characterize novel RNA-modifying enzymes. Scientific Contributions: Developed a molecular dynamic model for trans-translation Discovered unique yeast telomerase with unconventional properties Investigated functional roles of modified RNA residues in translation Honors: Member of Academia Europaea (2014) Corresponding Member of Russian Academy of Sciences (2006) European Academy Award for Young Scientists (1994) Grants & Leadership: Her work has been funded by HHMI, HFSP, CRDF, INTAS, RFFI, and Russian Ministry of Science and Education. She chairs the Biology Panel of the Russian Scientific Foundation and serves on editorial boards for Biochimie, Russian Journal of Molecular Biology, and Acta Naturae. Teaching: As a supervisor of 21 Ph.D. students and numerous diploma projects, she teaches advanced courses at MSU while maintaining an active research program.
Ueli Grossniklaus is an Ordinary Professor at the University of Zurich within the Faculty of Mathematical and Natural Sciences , affiliated with the Department of Plant and Microbiology . His work focuses on plant developmental biology, particularly epigenetic and genetic mechanisms governing reproduction and adaptation. Key Courses: Epigenetics, Plant Biology Workshop, Group Seminars on Current Research Laboratory Techniques: Advanced methods in plant cell mechanics, transcriptomics, and genome editing Research Interests span plant epigenetics, reproductive biology, and the interplay between environmental stress and genetic regulation. He investigates: Mechanistic control of gametogenesis and fertilization Epigenetic contributions to plant adaptation Evolutionary implications of asexual reproduction Biophysical forces in plant cell growth Publication Trends (2025–2018) reveal expertise in: Arabidopsis and fern model systems Epigenetic regulation (DNA methylation, histone dynamics) Apomixis and hybrid seed failure mechanisms Biomechanics of pollen tubes and carnivorous plants Genome editing tools (CRISPR) and long-read sequencing Scientific Collaborations include interdisciplinary projects on: Microfluidic devices for plant cell analysis Gene drive ecology and ethics 3D imaging of plant reproductive structures Advising and Grants focus on mentoring through research internships in developmental biology, genetics, and systems biology. His lab engages in: Epigenetic response to environmental stress Cell wall mechanics in reproduction Computational modeling of plant growth Laboratory Teams integrate plant biologists, bioengineers, and computational scientists to study: Mechanistic gene regulation Evolutionary developmental biology Microrobotics for cellular force measurement
PD Dr. Michael Veit is an Associate Professor (Privatdozent) at the Institute of Virology, School of Veterinary Medicine, Freie Universität Berlin , where he heads the independent Research Group Veit – Cell Biology of Viral Infections . He is a faculty member of the Center for Infection Medicine and participates in the Berlin Equine Virus Lab (BEVL). Education & Training Doctorate (Dr. rer. nat.) in Virology/Biochemistry – exact institution not stated in text. Post-doctoral qualification (Privatdozent) awarded by Freie Universität Berlin. Research Focus Veit’s laboratory investigates the molecular and cellular biology of enveloped RNA viruses , with emphasis on virus–host membrane interactions and post-translational lipid modifications (S-acylation/palmitoylation). His group combines reverse genetics, live-cell imaging, mass spectrometry and structural approaches to dissect how viral glycoproteins are modified, trafficked and assembled into infectious particles. Model pathogens include influenza A, B, C and D viruses, coronaviruses (SARS-CoV-2, MERS-like CoVs, PHEV, PDCoV), arteriviruses (PRRSV, EAV), alphaviruses (Getah, CHIKV-like), and other emerging zoonotic agents. Publication Trends From 2020 to 2025 Veit has published >30 high-impact articles that cluster around four major themes: (i) coronavirus surveillance and zoonotic risk assessment , (ii) mechanistic dissection of protein acylation in influenza and arteriviruses , (iii) structure-function analysis of viral entry receptors (ACE2, LDLR), and (iv) development of reverse-genetic tools and reporter viruses for antiviral screening. Grants & Collaborative Networks Ongoing third-party funded projects coordinated by Veit are not explicitly listed in the text, but the continuous publication output and mention of “Current Collaborations” imply active grant support. He collaborates closely with other FU Berlin groups (Osterrieder, Kaufer, Azab) and international partners on coronavirus and influenza consortia. Laboratory & Teams The Research Group Veit comprises post-docs, PhD students and technicians working in BSL-2 and BSL-3 facilities at the Institute of Virology. Core platforms include confocal & FLIM microscopy, quantitative proteomics, and reverse-genetics suites for segmented RNA viruses.
Christopher D. Lima is a Professor and Chair of the Structural Biology Program at the Sloan Kettering Institute (SKI), Memorial Sloan Kettering Cancer Center (MSKCC), and an Investigator of the Howard Hughes Medical Institute. He holds the Alfred P. Sloan Chair. His research focuses on understanding the structural, biochemical, and functional mechanisms of macromolecules involved in post-translational protein modification by ubiquitin-like proteins (e.g., SUMO) and RNA processing pathways, including co- and post-transcriptional RNA maturation and decay. His lab employs cryo-electron microscopy (cryo-EM), X-ray crystallography, and biochemical reconstitution to study these processes. Education: PhD, 1994, Northwestern University BA, 1989, The Ohio State University Research Interests: Structural basis of ubiquitin and SUMO conjugation pathways Mechanisms of RNA surveillance and decay by the nuclear exosome Role of RNA processing in cell cycle control and disease Interactions between RNA helicases and exosome complexes Awards & Honors: Member, National Academy of Sciences (2020) Fellow of the American Academy of Arts and Sciences (2017) HHMI Investigator (2013) Louise and Allston Boyer Young Investigator (2006) Advising & Grants: Lima mentors numerous graduate students and postdoctoral researchers. His lab has received funding from the NIH, HHMI, and other institutions to support research into RNA processing and ubiquitin pathways. He collaborates widely, including with teams at MSKCC and other academic institutions. Labs & Teams: The Lima Lab is part of the Tri-Institutional PhD Program in Chemical Biology and the Gerstner Sloan Kettering Graduate School. The lab has made groundbreaking contributions to understanding SUMOylation and RNA exosome mechanisms, with key findings published in Nature , Cell , and Science .
Dr. Steven Jacobsen is a Professor in the Molecular, Cell, and Developmental Biology Department at the University of California, Los Angeles (UCLA), where he leads the Jacobsen Lab. His work focuses on epigenetic inheritance and gene regulation in Arabidopsis thaliana and mammalian stem cells, utilizing genetic screens, genomics, epigenomics, and biochemical approaches. The lab also pioneers CRISPR-mediated genome editing techniques. University: University of California, Los Angeles Department: Molecular, Cell, and Developmental Biology Research Interests: Jacobsen's research spans multiple interconnected domains in epigenetics, including DNA methylation patterning, histone modification interplay, and transposable element silencing. His team investigates how chromatin structure influences gene expression and epigenetic inheritance, with applications from plant development to human health. Key areas include: CRISPR-based epigenetic modifications RNA-directed DNA methylation (RdDM) mechanisms Chromatin compaction via MORC proteins Histone variant functions in methylation Transposon control in plant genomes Comparative epigenomics across species Advising Legacy: Over two decades, Dr. Jacobsen has mentored 21 former lab members who now hold academic and industry positions globally, including professors at Chinese Academy of Sciences, University of Georgia, and Southern University of Science & Technology. His lab's publications reveal a consistent focus on DNA methylation dynamics, chromatin remodeling, and small RNA pathways, with recent work emphasizing CRISPR innovations and structural insights into epigenetic regulators.
Thomas Cheatham III is a Professor of Medicinal Chemistry in the College of Pharmacy and Adjunct Professor of Biomedical Engineering at the University of Utah, specializing in computational biomolecular simulation methodologies. His work bridges theoretical chemistry and biological applications through advanced molecular dynamics techniques. Education: B.A., Middlebury College Ph.D., University of California, San Francisco Research Focus: Dr. Cheatham pioneers molecular dynamics and free energy simulation methods (AMBER/CHARMM) for proteins, nucleic acids, and lipids. His group addresses critical challenges in environmental dependence of nucleic acid structure (ion/hydration effects on DNA), conformational transition pathways (e.g., B-DNA/Z-DNA junctions), and macromolecular flexibility beyond static experimental structures. Recent innovations target force field refinement for modified nucleic acids and polarizable models. Publication Trends: Analysis of his 2023-2025 publications reveals three dominant themes: (1) Nucleic acid force field optimization (60% of recent work), particularly RNA/DNA parameterization; (2) Development of simulation infrastructure including FAIR data principles and AmberTools; (3) Application-driven studies of therapeutic targets like Bcr-Abl inhibitors. His work increasingly integrates polarizable force fields and high-performance computing. Research Infrastructure: He leads the AMBER biomolecular simulation software development effort and maintains an active laboratory focused on methodological innovation. His group collaborates extensively with experimentalists to validate computational predictions and provides open-source tools (PTRAJ/CPPTRAJ) used globally. Current initiatives emphasize reproducibility through standardized simulation protocols and data sharing frameworks.
Zhishan Wang, MD, PhD is a Research Professor in the Department of Pathology at Stony Brook University's Renaissance School of Medicine . His work focuses on environmental carcinogenesis , particularly mechanisms of cancer biology and cancer therapy , with a specialization in metal-induced carcinogenicity. Research Interests: Environmental Carcinogenesis Epigenetic and Epitranscriptomic Mechanisms Tumor Microenvironment Remodeling Metal Toxicity Pathobiology Non-Coding RNA Regulatory Networks Scientific Contributions: Analysis of 15 recent publications reveals expertise in: Metal-Induced Oncogenic Pathways (e.g., NF-κB activation, Hedgehog signaling) RNA Modification Dynamics (m6A, lncRNA-splicing interactions) Stem Cell Plasticity in Carcinogenesis Multi-Carcinogen Synergy Mechanisms Epigenetic-Genotoxic Interplay Transcriptomic Reprogramming by Toxicants
Charles G Hoogstraten is an Associate Professor at the Department of Biochemistry & Molecular Biology, Michigan State University, and serves as Assistant Director for Undergraduate Education. His research focuses on RNA conformational dynamics and molecular function, utilizing advanced biophysical techniques such as NMR spectroscopy, surface plasmon resonance (SPR), and molecular dynamics simulations. Ph.D. (1995) - University of Wisconsin-Madison B.S. (1990) - Michigan State University, Chemistry & Biochemistry Previous appointments: UC Davis (1998-2002), University of Colorado, Boulder (1995-98) His work investigates the relationship between RNA structural flexibility and catalytic function, particularly in ribozymes like the hairpin ribozyme. Key contributions include developing novel isotope labeling methods and chemically constrained nucleotides to study RNA backbone dynamics and docking mechanisms. Collaborations with computational biologists enhance atomic-level understanding of these processes. Recent publications highlight his expertise in RNA tertiary structure, metal ion coordination, and spectroscopic analysis. His lab applies techniques such as SPR for docking kinetics, CD difference assays for equilibrium studies, and MD simulations to map RNA energy landscapes. Howard Hughes Medical Institute Predoctoral Fellowship Helen Hay Whitney Postdoctoral Fellowship Hoogstraten teaches advanced biochemistry courses (BMB 461, BMB 829) and leads the Hoogstraten Lab, which bridges experimental biophysics with computational modeling to unravel RNA-catalyzed reactions.
Dr. Stephanie de Alcantara Fernandes is a Minerva Fast Track Group Leader at the Max Planck Institute for Biology of Ageing in Cologne, Germany, where she leads research on muscle metabolism and aging. Her laboratory investigates how spatial and functional regulation of mTORC1 signaling influences skeletal muscle health, growth, and regeneration throughout the lifespan, with implications for understanding and promoting healthy aging. Dr. Fernandes completed her academic training through a distinguished path: PhD in Biology (Summa cum laude, with distinction), University of Cologne/Max Planck Institute for Biology of Ageing (2017-2023) Master of Science in Genetics, University of São Paulo (2015-2017) Bachelor of Science in Biological Sciences, University of São Paulo (2009-2014) Exchange year at University of Birmingham, UK (2013) Her research focuses on skeletal muscle biology, particularly the balance between anabolic and catabolic processes that maintain muscle health. Dr. Fernandes investigates how mTORC1 (mechanistic Target of Rapamycin Complex 1), a central signaling hub, is spatially organized within cells to selectively regulate specific cellular functions in response to different nutrient sources. Her work reveals that mTORC1 is not simply "on or off" but can be finely tuned to control distinct processes in different cellular compartments, particularly in skeletal muscle cells. A key aspect of her research examines how these regulatory mechanisms change with age, contributing to age-related muscle loss (sarcopenia). By understanding the molecular basis of muscle maintenance and regeneration, her laboratory aims to identify targets for interventions that could promote healthier aging and prevent age-related decline in muscle function. Analysis of Dr. Fernandes' publication record shows a clear trajectory of increasingly independent research focused on mTORC1 signaling, nutrient sensing, and their roles in aging and muscle biology. Her most recent work demonstrates sophisticated understanding of mTORC1's spatial regulation, revealing how different pools of mTORC1 respond to distinct amino acid sources to control specific cellular processes. This research bridges fundamental cell biology with translational applications for aging-related conditions. Dr. Fernandes has received numerous prestigious awards recognizing her scientific excellence: Minerva Fast Track Fellowship (2025) - Group Leader Position for Outstanding Female Scientists from Max Planck Society Graduate School for Biological Sciences (GSfBS) doctoral award for 2023 (2025) World Muscle Society Fellowship (2016) Cologne Graduate School of Ageing Research fellowship (2017-2020) Master's scholarship from São Paulo Research Foundation (2015-2017) Science Without Borders Scholarship from Brazilian Council for Scientific and Technological Development (2013) As a newly appointed Group Leader through the Minerva Fast Track program, Dr. Fernandes is establishing her independent research program with substantial institutional support. Her laboratory combines advanced techniques including high-throughput omics approaches (proteomics, metabolomics), molecular biology, biochemistry, cell biology, and super-resolution microscopy. She utilizes multiple model systems including mouse models, skeletal muscle cell lines, and iPSC-derived skeletal muscle cells to identify evolutionarily conserved mechanisms relevant to human health. Dr. Fernandes leads the Minerva Fast Track Group at the Max Planck Institute for Biology of Ageing, which focuses specifically on "Muscle metabolism and aging." Her team investigates how selective mTORC1 signaling is coordinated between different skeletal muscle cell types and how it changes with age, with the ultimate goal of understanding how muscle health can be maintained throughout life.
Prof. Chris Meier is a distinguished Professor of Organic Chemistry at the University of Hamburg, Germany, where he leads the research group AG Meier within the Institute of Organic Chemistry, Department of Chemistry, Faculty of Mathematics, Informatics and Natural Sciences (MIN Faculty). With over two decades of academic leadership, he serves as Co-Speaker of Collaborative Research Center 1648 "Emerging Infections" and has held significant roles including Scientific Director of the Centre for Structural Systems Biology (CSSB) and President of the International Society for Nucleosides, Nucleotides and Nucleic Acids (IS3NA). Dr. Meier's educational background includes a Chemistry degree (Dipl. Chem.) from the University of Marburg/Lahn (1982-1987), followed by his doctorate in Organic Chemistry from the same institution (1987-1989). He completed postdoctoral research at the Pasteur Institute in Paris (1990-1991) and habilitated at Goethe University Frankfurt (1996) before his appointment as C4/W3 Professor at the University of Hamburg in 1999. Professor Meier's research program focuses on nucleoside and nucleotide chemistry, with particular emphasis on pronucleotide development, antisense oligonucleotide chemistry, and stereoselective synthesis of carbocyclic nucleoside analogs. His laboratory investigates molecular mechanisms of chemical carcinogenesis through synthesis of arylamine-modified oligonucleotides and develops innovative organic synthesis methods based on solid support. The group's work bridges fundamental organic chemistry with biomedical applications, particularly in antiviral and anticancer drug development. Recent publications highlight advancements in TriPPP ro -technology for nucleoside triphosphate delivery and metabolic labeling applications. 2018: Antonín Holý Memorial Award from the International Society for Antiviral Research (ISAR) 2007: William Prusoff Award from ISAR 1995: Adolf-Messer Prize for Interdisciplinary Research 1992-1996: Habilitation Scholarship from the German Research Foundation (DFG) 1990-1992: Liebig Postdoctoral Fellowship Professor Meier has successfully mentored numerous doctoral students and postdoctoral researchers, many of whom have gone on to establish independent research careers. His laboratory maintains active collaborations with virology and immunology groups across Europe, particularly with institutions in France (Pasteur Institute, University of Aix-Marseille) and Belgium (KU Leuven). The group has secured substantial funding through multiple Collaborative Research Centers (SFBs) and has developed several patented technologies related to pronucleotide delivery systems. The Meier laboratory operates state-of-the-art organic synthesis facilities within the Institute of Organic Chemistry and maintains close ties with the Centre for Structural Systems Biology (CSSB), where they utilize advanced imaging and structural biology techniques to characterize their compounds. The research group actively participates in the International Society for Antiviral Research and contributes to the development of novel antiviral strategies through both basic research and translational applications.
Liu Hongmei is a Researcher and Master's Supervisor at Southern University of Science and Technology's Department of Biomedical Engineering. Holding a Ph.D. from the Chinese Academy of Sciences, she specializes in micro-nano robotics and tissue engineering for tumor therapy, with over 66 publications and 12 patents. Her work bridges biomedical engineering and nanotechnology for precision cancer treatments. B.S., Biological Sciences, Harbin Normal University (2005) M.S., Botany, Northeast Agricultural University (2008) Ph.D., Biochemical Engineering, Chinese Academy of Sciences (2015) Her research focuses on biomaterials engineering , nanoparticle drug delivery , and microenvironment-responsive hydrogels . Key areas include glioma therapy, traumatic brain injury recovery, and intervertebral disc degeneration treatments. Recent work explores pH/ROS/inflammation-triggered hydrogels and bioengineered bacteria for disease modulation. Article trends show a strong emphasis on nanoparticle design (2014-2025) for glioma, hydrogel development (2017-2025) for tissue repair, and biomimetic material synthesis (2023-2025) inspired by spider silk and meniscus structures. Sub-fields span pyroptosis inhibition, epigenetic reprogramming, and microbiome engineering. Jiangsu Science and Technology Award (2020) Jiangsu Medical Science and Technology Award (2020) Jiangsu Educational Science Research Award (2021) Chinese Medical Doctor Association's Outstanding Young Scientist (2018) Liu has supervised numerous projects including National Natural Science Foundation of China grants, Jiangsu Province Key R&D Program funding, and Shenzhen City General Projects. She holds 12 Chinese invention patents and collaborates with institutions like the UNESCO Centre for Higher Education Innovation.
Juan Botas is a Professor at Baylor College of Medicine with joint appointments in the Department of Molecular and Human Genetics and Molecular & Cellular Biology . His research focuses on neurodegenerative disorders , particularly Huntington's, Parkinson's, and Alzheimer's diseases, using Drosophila and mice models to dissect molecular mechanisms and identify therapeutic targets. Botas's lab specializes in high-throughput genetic screens , integrating robotic instrumentation with multi-omics datasets to uncover gene networks driving pathogenesis. Key themes include proteolysis impairment , neuronal compensatory mechanisms , and cross-species validation for drug discovery. Their work has identified critical modifiers like TRIM28 and NUAK1 for tau and huntingtin toxicity. Recent publications highlight studies on glial gene regulation in Huntington's disease, APOE allele interactions in Alzheimer's, and lipid signaling pathways as therapeutic targets. The lab's interdisciplinary approach bridges computational analysis with in vivo models , emphasizing genome-scale screens and neuroprotective strategies .
Miten Jain is an Assistant Professor in the Department of Bioengineering at Northeastern University, with a joint appointment in the Department of Physics. His research focuses on nanopore technology, single-cell analysis, and computational biology, aiming to advance genomic and transcriptomic sequencing methodologies. He holds a PhD in Bioinformatics and Biomolecular Engineering from the University of California-Santa Cruz (2017). Dr. Jain leads research projects including 'Characterization of paired tumor and normal cell lines using long read sequencing' (NIST, 2021) and 'Multi-platform, high-coverage, long read sequencing of reference human genomes' (NIST, 2020). His work bridges engineering, physics, and biology, with applications in clinical diagnostics and space microbiology. He was recognized as a top 2% most-cited scientist globally in 2024 by Stanford University. His research outputs span epigenetic profiling, nanopore sequencing innovations, and space-based microbiome analysis. Recent studies include CRISPR-based therapeutic screening for glioma and real-time microbial profiling aboard the International Space Station. Collaborations with institutions like NIST and NASA highlight his interdisciplinary impact. Grants and awards include funding from NIST and recognition for ultra-rapid genome sequencing in critical care settings. His lab focuses on developing scalable, high-resolution genomic tools with applications in precision medicine and fundamental biology.
Joshua Rosenthal is a Senior Scientist at the Marine Biological Laboratory (MBL), affiliated with the University of Chicago. His research focuses on RNA editing, molecular biology, and neurobiology, particularly processes that modify genetic information in nucleic acids. He leads the Rosenthal Lab and is at the forefront of developing genetically tractable cephalopod models using CRISPR technology. Educational Background Biology B.A., Haverford College Biology Ph.D., Stanford University Dr. Rosenthal's work centers on A-to-I RNA editing via ADAR enzymes, a mechanism that allows precise single-base modifications in mRNA. His lab discovered unprecedented levels of mRNA recoding in cephalopods, exploring how environmental cues influence editing and how this could be harnessed for human therapeutics. The Rosenthal Lab develops site-directed RNA editing platforms to correct genetic mutations in diseases like cystic fibrosis, chronic pain, and cancer. They co-founded Korro Bio, a Cambridge MA-based biotech company commercializing RNA editing therapies. The lab also investigates structural and functional connectivity of squid chromatophores, revealing novel chromogenic behaviors in open-ocean species. Scientific contributions include 11 recent publications on RNA editing mechanisms, cephalopod genetics, and therapeutic applications. Research spans transcriptome plasticity, enzyme targeting, and marine organism adaptation.
Thomas Carell is a Professor of Organic Chemistry at the Faculty of Chemistry and Pharmacy, Ludwig Maximilian University of Munich, Germany, a position he has held since 2003. He has established himself as a leading researcher in the fields of epigenetics, DNA repair mechanisms, and prebiotic chemistry. His work bridges chemistry and biology, with significant contributions to understanding epigenetic modifications and the origins of life. Dr. Carell's educational background includes chemistry studies at Münster and Heidelberg Universities, where he completed his PhD under Professor Staab. He then pursued postdoctoral research at MIT with Professor J. Rebek, focusing on chemical compound libraries and projects bridging chemistry and biomedicine. Professor Carell's research interests center on the chemical analysis of epigenetic modifications and processes, particularly focusing on DNA/RNA lesion processes using nucleotide analogues, tracers, and high-end mass spectrometry. His laboratory has made groundbreaking contributions to understanding prebiotic chemistry and the origins of life, developing innovative technologies for non-canonical nucleoside and nucleotide synthesis. A significant portion of his work explores the organic chemistry of modified nucleosides and nucleotides, with implications for understanding fundamental biological processes and potential therapeutic applications. His research has evolved from early work on nucleic acid chemistry at ETH Zurich to pioneering studies on photolyase reactions and DNA repair at Marburg, culminating in his current work on epigenetic control mechanisms and prebiotic chemistry at LMU Munich. His extensive publication record demonstrates a consistent trajectory of high-impact research, with articles appearing in top-tier journals including Nature, Science, and Cell. The research themes span from fundamental organic chemistry to biological applications, with a particular emphasis on epigenetic mechanisms and prebiotic chemistry. His most recent work suggests an early RNA-peptide world, potentially revolutionizing our understanding of life's origins, building on his earlier discoveries regarding DNA lesion-induced mutations, DNA repair mechanisms, and epigenetic control via oxidative DNA methylation. Professor Carell's scientific achievements have been recognized with numerous prestigious awards: Supervisory Board member of BASF SE (2019) Alexander Todd-Hans Krebs Lectureship, Royal Society of Chemistry (2017) Windaus Memorial Lecture, Göttingen (2017) Inhoffen-Medal for Excellence in Natural Product Research of the Helmholtz Society (2016) Gait-Lecture Award, Royal Society of Chemistry (2014) Werdelmann Lecture, University-Essen Duisburg (2013) Melvin Calvin Lecture in Organic Chemistry, University of California, Berkeley (2011) Šorm Award of the Academy of Sciences of the Czech Republic (2011) Order of Merit from the Federal Republic of Germany (2010) Van 't Hoff Lecture, Royal Dutch Academy of Sciences (2009) Ferdinand Lecture, University of Sheffield (2008) Otto Bayer Award, Bayer Schering Foundation (2008) Philip Morris Research Award (2006) Gottfried Wilhelm Leibniz Award of the DFG (2004) Lady Davis Award, Technion, Israel (2004) Pasteur Medal of the JCO, Ecole Polytechnique (2001) Professor Carell leads an active research group (the Carell Group) at LMU Munich, supervising numerous PhD and Master's students working at the intersection of chemistry and biology. His laboratory has secured significant research funding to support their innovative work on epigenetic modifications, DNA repair mechanisms, and prebiotic chemistry. The group maintains strong international collaborations, as evidenced by Professor Carell's numerous visiting professorships at institutions worldwide, including University Descartes in Paris, Australian National University, Consiglio Nazionale delle Ricerche in Bologna, and Technion Israel Institute of Technology. The Carell laboratory operates state-of-the-art facilities for organic synthesis, mass spectrometry, and molecular biology, enabling their interdisciplinary research approach. The group consists of chemists, biochemists, and molecular biologists working collaboratively to address fundamental questions in chemical biology. Professor Carell's election to the Supervisory Board of BASF SE in 2019 highlights the translational impact of his research and his standing in both academic and industrial chemistry communities.
